Administration of granulocyte colony-stimulating factor during remission induction therapy with all-trans retinoic acid for acute promyelocytic leukemia

Granulocyte colony-stimulating factor (G-CSF) enhances the differentiation of acute promyelocytic leukemia (APL) cells induced by all-trans retinoic acid (ATRA) in vitro. Accordingly, we initiated a pilot study on G-CSF in APL patients who developed neutropenia and severe infection during remission...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of hematology Vol. 64; no. 3-4; p. 213
Main Authors Usuki, K, Nishizawa, Y, Endo, M, Osawa, M, Kitazume, K, Iki, S, Watanabe, M, Urabe, A
Format Journal Article
LanguageEnglish
Published Japan 01.10.1996
Subjects
Adult
Aged
Antineoplastic Agents - therapeutic use
Drug Therapy, Combination
Female
Granulocyte Colony-Stimulating Factor - administration & dosage
Humans
Leukemia, Promyelocytic, Acute - blood
Leukemia, Promyelocytic, Acute - drug therapy
Leukemia, Promyelocytic, Acute - pathology
Male
Middle Aged
Remission Induction
Tretinoin - therapeutic use
Online AccessGet more information

Cover

More Information
Summary:Granulocyte colony-stimulating factor (G-CSF) enhances the differentiation of acute promyelocytic leukemia (APL) cells induced by all-trans retinoic acid (ATRA) in vitro. Accordingly, we initiated a pilot study on G-CSF in APL patients who developed neutropenia and severe infection during remission induction therapy with ATRA. Seven out of nine treated patients displayed a marked increase in granulocyte counts without leukemic regrowth, and two displayed a dramatic decrease in leukemic blasts. However, leukemic regrowth occurred in two patients under treatment for post-ATRA relapse. Our findings suggest that administration of G-CSF combined with ATRA can improve the hematological state in APL patients not previously receiving ATRA therapy.
ISSN:0925-5710
DOI:10.1016/0925-5710(96)00471-9